Guest guest Posted October 27, 2004 Report Share Posted October 27, 2004 Date: Tue, 26 Oct 2004 13:39:03 EDT From: gateswill@... Subject: new drug study- MBP8298 OK, I'll bite--is MBP8298 really LDN or is it some other newer drug? Daphne --------------------------------------------------------- Hi Daphne -- No, it's not LDN. Here's what I read: ---------------------------------------------------------- MBP8298 is a synthetic segment of myelin basic protein. It is given by intravenous infusions at intervals of several months. The researchers have been involved in the development of MBP8298 for more than 20 years. Most recently, a four-year Phase II study involved 32 people with either primary-progressive or secondary-progressive MS. Sixteen participants were given 500 mg of MBP8298 intravenously every six months for two years and the remaining 16 received a placebo. This was followed by an open label phase in which both groups received MBP8298. Five out of the 16 participants in the treated group became worse (as measured by EDSS) compared to nine out of 16 participants in the placebo group. Because of the small size of the study group, these findings did not reach statistical significance. Using two secondary outcomes (22-metre timed walk and foot taps) there was a trend for participants in the treated group to score better than placebo, although this difference did not reach statistical significance. --------------------------------------------------- Here is more: http://www.mssociety.ca/en/research/medmmo-mbpstudy-update-mar04.htm Hope this helps.... -- Maureen Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.